Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David-Alexandre C. Gros
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Beta
- 0.94
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -4.45
Financials
Net Income
$-31.63MEBITDA
$-14.11MFree Cash Flow
$-22.68MEPS (diluted)
$-0.27Shares Outstanding (diluted)
113.63M+2634.9%Operating Expenses
$22.87MCash & Debt
$88.76MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-45.62M | $-0.56 |
| 2024 | $0.00 | $-36.18M | $-0.75 |
| 2023 | $0.00 | $-116.54M | $-4.73 |
| 2022 | $0.00 | $-87.97M | $-6.16 |
| 2021 | $0.00 | $-34.51M | $-2.33 |
| 2020 | $0.00 | $-22.81M | $-17.16 |
| 2019 | $0.00 | $-16.01M | $-24.42 |
| 2018 | $0.00 | $-14.06M | $-28.11 |
| 2017 | $0.00 | $-13.12M | $-41.40 |
| 2016 | $0.00 | $-37.96M | $-398.52 |
| 2015 | $0.00 | $-45.09M | $-325.62 |
| 2014 | $0.00 | $-23.30M | $-583.20 |
| 2013 | $0.00 | $-15.72M | $-112.33 |
| 2012 | $0.00 | $-9.65M | $-68.76 |
Valuation
ELDNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·18h ago·Negative
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week 2026 Annual Meeting taking place in Denver, CO, from October 21-25, 2026.
View source ↗ - Newsglobenewswire.com·27d ago·Positive
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection will take place at the upcoming International Congress of The Transplantation Society in Sydney, Australia, from September 20–23, 2026.
View source ↗ - Newsglobenewswire.com·33d ago·Negative
… LEGACY trial of tegoprubart in kidney transplantation in Q4 2026 IRVINE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced significant progress across multiple tegoprubart development programs in kidney allotransplantation and islet cell transplantation.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
…ts and short-term investments of $88.8 million as of June 30, 2026 IRVINE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its second quarter 2026 operating and financial results and provided recent business highlights.
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.20 per share
Typical surprise +4.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.27 vs $-0.16miss
- Wed, May 13$-0.33 vs $-0.22miss
- Thu, Mar 19$-0.10 vs $-0.20beat
- Fri, Nov 14$-0.21 vs $-0.22beat
- Thu, Aug 14$-0.13 vs $-0.23beat
- Wed, May 14$-0.08 vs $-0.28beat
Estimates and results for ELDN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ELDN officers and directors.
- Bought
- $26.5m
- Sold
- —
22 trades
0 trades
- Bvf Partners L P/ilbought
- Bvf Partners L P/ilbought
- Bvf Partners L P/ilbought
- Bvf Partners L P/ilbought
- Bvf Partners L P/ilbought
- Bvf Partners L P/ilbought
- Bvf Partners L P/ilbought
- Bvf Partners L P/ilbought
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ELDN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.